Damora Therapeutics, Inc. - Current Ratio

The Current Ratio as of August 2026 (TTM) for Damora Therapeutics, Inc. (GLTO) is 22.48

According to Damora Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 22.48. This represents a change of 106.34% compared to the average of 10.90 of the last 4 quarters.

Damora Therapeutics, Inc. (GLTO) Historical Current Ratio (quarterly & annually)

How has GLTO Current Ratio performed in the past?

The mean historical Current Ratio of Damora Therapeutics, Inc. over the last ten years is 13.59. The current 22.48 Current Ratio has changed 16.45% with respect to the historical average. Over the past ten years (40 quarters), GLTO's Current Ratio was at its highest in in the December 2020 quarter at 30.42. The Current Ratio was at its lowest in in the September 2019 quarter at 0.

Damora Therapeutics, Inc. (GLTO) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Damora Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Damora Therapeutics, Inc. (GLTO) Average Current Ratio

How has GLTO Current Ratio performed in the past?

The current Current Ratio of Damora Therapeutics, Inc. (GLTO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Damora Therapeutics, Inc. (GLTO) Current Ratio vs. Peers

How is GLTO’s Current Ratio compared to its peers?

Damora Therapeutics, Inc.’s Current Ratio is greater than TransCode Therapeutics, Inc. (3.11), less than Phio Pharmaceuticals Corp. (66.93), greater than Aprea Therapeutics, Inc. (8.92), greater than Kiora Pharmaceuticals, Inc. (6.68), greater than IN8bio, Inc. (10.50), greater than Acurx Pharmaceuticals, Inc. (3.78), greater than Aptevo Therapeutics Inc. (3.36), greater than Lyra Therapeutics, Inc. (1.71), greater than Adial Pharmaceuticals, Inc. (3.18), greater than BioCardia, Inc. (0.41),

Build a custom stock screener for Damora Therapeutics, Inc. (GLTO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Damora Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Damora Therapeutics, Inc. (GLTO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Damora Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.